MX2023007154A - Dispersiones solidas amorfas. - Google Patents

Dispersiones solidas amorfas.

Info

Publication number
MX2023007154A
MX2023007154A MX2023007154A MX2023007154A MX2023007154A MX 2023007154 A MX2023007154 A MX 2023007154A MX 2023007154 A MX2023007154 A MX 2023007154A MX 2023007154 A MX2023007154 A MX 2023007154A MX 2023007154 A MX2023007154 A MX 2023007154A
Authority
MX
Mexico
Prior art keywords
solid dispersions
amorphous solid
therapy
processes
formula
Prior art date
Application number
MX2023007154A
Other languages
English (en)
Inventor
Faiza Laredj
Rosanna Chirico
Aymeric Ousset
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MX2023007154A publication Critical patent/MX2023007154A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

La presente invención se refiere a dispersiones sólidas de compuesto amorfo de fórmula (I), y una matriz polimérica, sus procesos de preparación y sus usos en terapia. (ver Fórmula).
MX2023007154A 2020-12-18 2021-12-16 Dispersiones solidas amorfas. MX2023007154A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20215253 2020-12-18
PCT/EP2021/086061 WO2022129267A1 (en) 2020-12-18 2021-12-16 Amorphous solid dispersions

Publications (1)

Publication Number Publication Date
MX2023007154A true MX2023007154A (es) 2023-06-28

Family

ID=73855649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007154A MX2023007154A (es) 2020-12-18 2021-12-16 Dispersiones solidas amorfas.

Country Status (15)

Country Link
US (1) US20240000769A1 (es)
EP (1) EP4262756A1 (es)
JP (1) JP2023553457A (es)
KR (1) KR20230121867A (es)
CN (1) CN116685308A (es)
AR (1) AR124406A1 (es)
AU (1) AU2021401128A1 (es)
CA (1) CA3201298A1 (es)
CL (1) CL2023001395A1 (es)
CO (1) CO2023007098A2 (es)
IL (1) IL303688A (es)
MX (1) MX2023007154A (es)
PE (1) PE20240021A1 (es)
TW (1) TW202241424A (es)
WO (1) WO2022129267A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160668A1 (en) * 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
CN106232144B (zh) * 2014-03-18 2019-12-06 武田药品工业株式会社 固体分散体
RS60933B1 (sr) * 2014-10-08 2020-11-30 UCB Biopharma SRL Derivati tetrahidroizohinolina
BR112018070363A2 (pt) * 2016-04-13 2019-01-29 Ucb Biopharma Sprl derivados de tetraidroisoquinolina
KR20220029686A (ko) 2019-07-01 2022-03-08 유씨비 바이오파마 에스알엘 D1 양성 알로스테릭 조절제로서의 치환된 테트라히드로이소퀴놀린 유도체

Also Published As

Publication number Publication date
US20240000769A1 (en) 2024-01-04
KR20230121867A (ko) 2023-08-21
IL303688A (en) 2023-08-01
CO2023007098A2 (es) 2023-06-09
AU2021401128A1 (en) 2023-07-13
WO2022129267A1 (en) 2022-06-23
CL2023001395A1 (es) 2023-12-29
EP4262756A1 (en) 2023-10-25
PE20240021A1 (es) 2024-01-04
CA3201298A1 (en) 2022-06-23
TW202241424A (zh) 2022-11-01
CN116685308A (zh) 2023-09-01
JP2023553457A (ja) 2023-12-21
AR124406A1 (es) 2023-03-22

Similar Documents

Publication Publication Date Title
EP4265299A3 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
CN111601610A8 (zh) 使用布劳特氏菌属菌株治疗疾病的组合物和方法
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
CA3082011A1 (en) Methods of using substituted pyrazole and pyrrole compounds and for treatment of hyperproliferative diseases
GEP20146125B (en) Aminopyrimidines as syk inhibitors
GEP20166443B (en) Heterocyclic compound and use thereof
WO2018189646A8 (en) AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
AU2020317609A8 (en) Novel heteroaryl-triazole compounds as pesticides
ZA202207729B (en) Solid state form of pyroxasulfone
EP4342473A3 (en) Compounds useful in hiv therapy
AU2020231934A8 (en) Compounds useful in HIV therapy
ZA202203603B (en) Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
WO2021257730A3 (en) Cells modified by a cas12i polypeptide
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
MX2022003037A (es) Compuestos antibacterianos.
AU2018246053A8 (en) IP6K inhibitors
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
PH12020550476A1 (en) Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration
TN2021000025A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
WO2015042414A8 (en) Multicyclic compounds and methods of using same
MX2023010941A (es) Compuestos antibacterianos.
MX2023010948A (es) Compuestos antibacterianos.
MX2023007154A (es) Dispersiones solidas amorfas.
EP2029615B8 (en) A process for the preparation of an oxaliplatin